Novo Nordisk study shows cardiovascular benefits of semaglutide

Novo Nordisk has announced new clinical trial results from SUSTAIN 6, a new study assessing the performance of its investigational glucagon-like peptide-1 analogue semaglutide.

Assessing the once-weekly therapy's performance among 3,297 people, it was shown that the drug significantly reduced the risk of cardiovascular death or non-fatal heart attack and stroke by 26 percent compared to placebo, when added to standard of care in type 2 diabetes at high cardiovascular risk.

There was also a significant 39 percent decrease in non-fatal stroke, a 26 percent decrease in non-fatal heart attack and a neutral outcome in terms of cardiovascular death rates after two years of treatment.

Fewer serious adverse events were seen with semaglutide compared to placebo, although treatment discontinuation due to adverse events was more frequent with semaglutide, mainly due to gastrointestinal events.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "The results of SUSTAIN 6 support the strong potential of once-weekly semaglutide in type 2 diabetes treatment and we look forward to regulatory submission later this year."

To date, the drug has now completed six phase IIIa clinical trials for the treatment of adults with type 2 diabetes.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.